Company Overview and News
Sept 18 (Reuters) - Canada’s main stock index edged higher on Tuesday, boosted by gains in energy companies as oil prices rose on signs that OPEC may not raise output to address shrinking supplies from Iran.
NGD ELD NGDAF FQVLF FQM NGD EGO
Sept 11 (Reuters) - Canada’s main stock index touched over three-month lows on Tuesday led by declines in materials companies amid the ongoing Sino-U.S. trade dispute and uncertainty over the future of NAFTA trade pact.
FR OMI IMO ABX OMI ACBFF NPIFF IMO SU NPI OROXF RNX RNX.WT ACB RNKLF CNQ BRPIF FQVLF AG FQM ABX SU
Sept 5 (Reuters) - Canada’s main stock index slipped on Wednesday, as energy stocks declined in tandem with a fall in oil prices and uncertainty around trade talks persisted.
ACBFF CHHHF TD SU NSU APH 2899 FQVLF FQM TD ZIJMF SU TNTTF SAWLF PDS ZIJMY MFC ACB 0945 CNQ MFC APHQF
LONGUEUIL, Quebec, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Highland Copper Company Inc. (TSX-V: HI, OTCQB: HDRSF) (the “Company”) and Copper Range Company (“CRC”), a wholly-owned subsidiary of First Quantum Minerals Ltd., have agreed to extend the period to complete the acquisition of the White Pine project to [November 30, 2018]. The final closing of the acquisition is subject to releasing CRC from certain environmental obligations associated with the remediation and closure plan of the historical White Pine mine site, and replacing the related environmental bond posted by CRC.
FQVLF HI FQM
Aug 30 (Reuters) - Optimism about reaching a new NAFTA deal by the end of this week lifted Canada’s main index on Thursday and energy companies provided a boost as oil prices rose.
TNTTF ACBFF CGC TD TECK ACB APH WEED FQVLF AEM TCKRF APHQF FQM TD CBWBF
Cobalt miner news - BHP seeking to add cobalt sulphate from Nickel West operation. China Molybdenum net profit set to surge between 271.21% and 295.16%.
SIE PIO CLA PANRF BLT CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER BBL CSSQF BHPLF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF GAL CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT BHPBF HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM BHP CNJ AZRMF HLPCF BPL BHP OZL ARV
2018-08-21 reuters - 1
(Reuters) - Canada’s main stock index rose on Tuesday as a rally in oil prices pushed energy shares higher.
ECN ACBFF MEG ECA TXG CGC SU LUC ECA RNX RNX.WT TWMJF ACB LUCRF RNKLF APH CNQ WEED FQVLF MEGEF APHQF FQM TORXF SU
2018-08-20 reuters - 1
Aug 20 (Reuters) - Canada’s main stock index rose on Monday as rising metal prices led to gains in material stocks, with hopes of resolution in the U.S.-China trade dispute boosting the sentiment.
NGD ABX CROJF ACBFF NGDAF K COP NGD CGC TWMJF ACB KGC CNQ WEED FQVLF FQM ABX
Aug 1 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 57.24 points, or 0.35 percent, to 16,376.77. * Lagging shares were Aphria Inc, down 8.2 percent, First Quantum Minerals Ltd, down 7.9 percent, and Maxar Technologies Ltd, lower by 6.4 percent. * Leading the percentage gainers were Enercare Inc, up 52.8 percent, Corus Entertainment Inc, up 8.4 percent, and Kirkland Lake Gold Ltd , higher by 6.
KGI KGI.DB.A ACBFF KGI.DB ACB CJREF APH CJR.B BDRPF FQVLF APHQF FQM MAXR KL
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ACLTF CNUTF FQVLF FQM CDUAF CU
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...